Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase 3 Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome

Trial Profile

A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase 3 Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Mar 2019

At a glance

  • Drugs Macitentan (Primary)
  • Indications Down syndrome; Eisenmenger complex
  • Focus Registrational; Therapeutic Use
  • Acronyms MAESTRO
  • Sponsors Actelion Pharmaceuticals
  • Most Recent Events

    • 02 Jan 2019 Results evaluating the efficacy and safety of the endothelin receptor antagonist macitentan in patients with Eisenmenger syndrome, published in the Circulation.
    • 30 Aug 2017 Results of MAESTRO study (n=226) and its haemodynamic substudy (n=39) presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology
    • 23 Jan 2017 Results published in an Acetelion Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top